Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMKBOS2)

• Drug Name: Levosimendan Drug Info
• Synonyms: Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
• Therapeutic Class: Cardiotonic Agents
• Cross-matching ID:
  PubChem CID: 3033825
  ChEBI ID: CHEMBL2051955
  CAS Number: CAS 141505-33-1
  TTD Drug ID: D0C4HG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Oxidative phosphorylation	2.08	0.00e+0	93/133 (69.92%)	COX7B;COX5B;COX7A2;...
Parkinson disease	2.08	0.00e+0	176/249 (70.68%)	COX7B;COX5B;BAX;...
Ribosome	1.95	4.33e-3	113/158 (71.52%)	RPL36;RPS27L;RPS26;...
DNA replication	1.90	3.25e-3	34/36 (94.44%)	PCNA;POLE2;MCM6;...
Nitrogen metabolism	1.86	7.80e-3	16/17 (94.12%)	CA2;CPS1;CA12;...
Diabetic cardiomyopathy	1.81	1.41e-2	162/203 (79.8%)	COX7B;COX5B;COX7A2;...
Mineral absorption	1.75	2.88e-2	48/60 (80%)	MT1F;MT1E;MT1H;...
Prion disease	1.72	3.57e-2	209/273 (76.56%)	COX7B;COX5B;C7;...
Homologous recombination	1.70	4.26e-2	35/41 (85.37%)	RBBP8;BRIP1;BRCA1;...
Thermogenesis	1.69	3.96e-2	173/232 (74.57%)	COX7B;MGLL;COX5B;...
Protein digestion and absorption	-1.69	4.64e-2	78/103 (75.73%)	CPA1;CELA3A;KCNQ1;...
Human T-cell leukemia virus 1 infection	-1.70	4.51e-2	197/219 (89.95%)	SRF;HLA-DQB1;CRTC3;...
Prostate cancer	-1.73	3.00e-2	93/97 (95.88%)	PIK3CD;MAPK1;IKBKG;...
Th17 cell differentiation	-1.73	3.21e-2	95/107 (88.79%)	NFKBIB;STAT6;IL4;...
Sphingolipid signaling pathway	-1.74	3.25e-2	106/119 (89.08%)	PPP2R3B;PPP2R5E;HRAS;...
JAK-STAT signaling pathway	-1.75	2.84e-2	146/162 (90.12%)	IL3;SOS1;IL12RB1;...
Acute myeloid leukemia	-1.77	2.48e-2	66/67 (98.51%)	STAT5A;HRAS;CSF2;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.78	2.31e-2	79/89 (88.76%)	PIK3CD;CD3D;MAPK1;...
Phagosome	-1.79	2.57e-2	118/152 (77.63%)	CTSL;RAB7A;ATP6V0C;...
Staphylococcus aureus infection	-1.80	2.38e-2	72/95 (75.79%)	CFH;CAMP;PTAFR;...
Osteoclast differentiation	-1.83	2.72e-2	117/127 (92.13%)	CSF1;PIK3CD;MAPK1;...
Choline metabolism in cancer	-1.83	3.18e-2	84/98 (85.71%)	PIK3CD;MAPK1;CHKB;...
Tuberculosis	-1.84	3.54e-2	159/180 (88.33%)	RAB7A;ATP6V0C;ARHGEF12;...
T cell receptor signaling pathway	-1.84	4.42e-2	93/104 (89.42%)	ICOS;HRAS;IL10;...
Toll-like receptor signaling pathway	-1.92	1.82e-2	94/104 (90.38%)	PIK3CD;MAPK1;IKBKG;...
GnRH secretion	-1.94	2.72e-2	60/64 (93.75%)	PLCB2;KISS1;HRAS;...
Th1 and Th2 cell differentiation	-1.98	4.08e-2	80/92 (86.96%)	NFKBIB;STAT6;RUNX3;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼